The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

They told me it was effective, and I knew mailing a Cologuard box back would be pretty dang easy.” Cologuard — a simple way ...

This medical services stock is in a buy zone of a cup base. The firm's losses are dwindling.

A new test could be an option for the 40% of Americans over age 45 who are not up to date with screenings. The Food and Drug Administration provided final approval on Monday for a new colorectal ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide ...

Earlier this week, Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare ...

As new colorectal cancer screening guidance draws attention to the growing number of testing options, the American ...

May 27 (Reuters) - People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among recommendations ‌by the ...

An investigational blood test for early detection of colorectal cancer (CRC) in average-risk adults met the primary endpoints of sensitivity and specificity in the PREEMPT CRC study, the largest study ...

When David Thau, a lobbyist in Washington, D.C., was 34, he periodically experienced pain in his stomach, irregular bowel movements, blood in his stool and vomiting, and he visited doctors who ...

A major European trial has pushed colonoscopy back into the medical spotlight. After 13 years, the NordICC study found that ...